BACKGROUND: Therapeutic advances have extended survival for patients with myeloma, who may develop secondary cancers. METHODS: Using the population-based Surveillance, Epidemiology, and End Results registry (2004-2015), the authors examined the characteristics, overall and cause-specific survival, and cumulative incidence function of cancer-related death among patients with myeloma with secondary cancers of the breast, prostate, lung, colon/rectum, or bladder or melanoma. Each patient was matched based on age, sex, race, and year of diagnosis to 50 controls from a general population who were diagnosed with the index cancer. RESULTS: Patients with myeloma with breast, prostate, or lung cancer were more commonly diagnosed at an early stage, whereas the stage distribution did not differ significantly among patients with melanoma, colorectal cancer, or bladder cancer. For all studied cancers except those of the lung, overall mortality was significantly higher among patients with myeloma compared with controls (hazard ratios, 1.84-2.81). However, the cumulative incidence function of cancer-related death did not differ (subhazard ratios, 0.84-0.99) and was surpassed by myeloma-related deaths (23% to 35% at 5 years). In patients with lung cancer, cancer-related mortality was uniquely lower among patients with myeloma (subhazard ratio, 0.59; 95% confidence interval, 0.52-0.68), even after adjustment for stage of disease. There was no significant difference noted with regard to noncancer deaths for any studied solid tumor. Use of surgery (evaluated in patients with nonmetastatic tumors, and in addition matched by disease stage) did not differ between cases and controls, except for fewer prostatectomies being noted among patients with myeloma (odds ratio, 0.56; 95% confidence interval, 0.42-0.74). CONCLUSIONS: The results of the current study support curative treatment approaches to secondary cancers among patients with myeloma while highlighting the need for ongoing active myeloma management. Cancer 2019;125:550-558.
INTRODUCTION
Advances in the therapeutic armamentarium for patients with plasma cell myeloma have led to significant improvements in overall survival (OS). 1, 2 For example, the median OS of patients with newly diagnosed myeloma at the Mayo Clinic increased from 2.5 years for 1971 through 1996 to 6.1 years for 2006 through 2010. 3, 4 Similar advances have been described in population-based studies from the United States, Sweden, Greece, and Germany. 1, [5] [6] [7] Longer survival results in a more common clinical scenario of secondary primary malignancies (SPMs) among survivors of myeloma, an issue of increasing importance recognized by the International Myeloma Working Group. 8 Previous characterizations of SPMs in patients with myeloma estimate that the cumulative incidence of an SPM is approximately 3% to 5%. 9, 10 Because of the ongoing risk of myeloma progression and exposure to high-dose therapy and autologous stem cell transplantation, as well as long-term maintenance therapy with immunomodulatory drugs, patients who experience SPMs may be at a disadvantage with regard to treatment options or subsequent outcomes of the second cancer. Studies of SPMs occurring among patients with other hematologic malignancies such as chronic lymphocytic leukemia (CLL) or Waldenstrom macroglobulinemia have demonstrated shortened OS compared with the general population diagnosed with the same cancers. [11] [12] [13] These disparities have been postulated to result from an older age at the time of diagnosis, as well as potentially less intense treatments of SPMs among survivors. Immune dysregulation related to hematologic
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From the perspective of treatment planning and prognostic counseling, it is important for patients and clinicians to separate the risk of dying of myeloma from that of dying of the SPM. However, to our knowledge, the relative contributions of myeloma and SPMs to overall mortality remain to be investigated. Furthermore, patterns of care and outcomes among patients with myeloma who develop common cancers in the modern era are unknown. The objective of the current study was to describe the clinical characteristics and OS and disease-specific survival, as well as the use of curative surgery, among patients with myeloma with common solid tumors in comparison with the general population of patients diagnosed with the same cancers.
MATERIALS AND METHODS

Data Source
We extracted data from the Surveillance, Epidemiology, and End Results (SEER) registry regarding patients diagnosed between 2004 and 2015 with the 6 most common solid tumors in the United States: breast cancer (women only), prostate cancer, lung cancer, colorectal cancer, bladder cancer, or malignant melanoma.
14 The SEER program collects cancer incidence, treatment, and outcome data from 18 geographical areas of the United States that currently cover approximately 30% of the US population. 15 The current study used deidentified public data and was conducted according to the principles of the Declaration of Helsinki, but was not subject to a formal human subject protection review. We created a separate cohort for each "index cancer" and excluded cases diagnosed at autopsy or without any follow-up for survival. Leveraging the fact that the SEER program collects information regarding up to 10 sequential malignancies for all individuals, we identified patients with myeloma within each cohort, defined as patients with myeloma (including "smoldering myeloma") diagnosed between 1994 and 2015, at least 180 days before the index solid tumor.
For the purposes of comparing survival, we matched patients with myeloma to 50 randomly sampled controls in each cancer cohort by age (in 5-year intervals), sex, race, and year of diagnosis (in 3-year intervals). A separate matching procedure, in addition including stage of the cancer, was conducted for the comparison of the use of surgery in patients with localized or regional disease. We used "summary stage," a general assignment of the extent of cancer spread in the SEER registry mapped to changing staging systems over time, which was available for all studied cancers throughout the covered timeframe. 16 The summary stage is categorized as localized, regional (with spread by direct extension to adjacent organs or metastasis to regional lymph nodes), distant (metastatic spread to other organs), or in situ (only occurring in patients with bladder cancer).
Variables
When studying mortality in the presence of 2 malignancies (myeloma and secondary solid cancer), it is critical to distinguish risk related to each cause. Therefore, apart from OS (calculated as the time from diagnosis of the index cancer to death from any cause), we studied 2 measures of cause-specific mortality: cancer-specific survival (CSS) and cumulative incidence function (CIF) of cancer death. The CSS and CIF provide different perspectives. CSS (the time from diagnosis of the solid cancer to death ascribed to this cancer on a death certificate) compares only mortality due to the index cancer (but not due to myeloma or other causes), and thus provides an answer to the question: "does the clinical or biological behavior of a solid cancer differ between myeloma patients and controls?" In contrast, CIF compares the reallife absolute risk of dying of the cancer, accounting for other existing competing causes of death, and thus provides the answer to the question: "do myeloma patients have a higher risk of dying from the index solid cancer, considering concurrent risk of dying from myeloma?." 17 CIF generally is considered to be a more patient-oriented measure, although both endpoints contribute important information. 18 Receipt of surgery was ascertained only for those patients with localized or regionally advanced tumors, excluding those with distant metastases. Cancers that are localized or locally advanced generally are considered to be resectable and these patients may be treated with curative surgery.
Statistical Analysis
We compared patient characteristics using the 2-sided chi-square test in the matched cohort, but did not conduct statistical tests in the very large primary populationbased data set, in which even minuscule differences would appear to be statistically significant. Receipt of surgery was compared in a conditional logistic model stratified
Cancer February 15, 2019 based on the matching set (each set containing patients of the same age, sex, and race with the same year of diagnosis and disease stage group), reporting conditional odds ratios (OR). OS and CSS were compared in Cox models with standard errors clustered on the matched set, reporting hazard ratios (HRs). To account for the risk of mortality independent of stage of disease, we also evaluated models stratified based on the SEER summary stage. The CIF was compared using an analogous competing-risk Fine-Gray model, reporting subhazard ratios for death from the index cancer, and accounting for clustering within the matching sets. 19 All estimates were generated with 95% confidence intervals (95% CIs), and all analyses were conducted using the National Cancer Institute's SEER*Stat 8.3.5 software (available at https://seer.cancer.gov/seerstat) and Stata/MP 15.1 statistical software (StataCorp LLC, College Station, Texas). A P value < .05 was considered to be statistically significant.
RESULTS
For each of the 6 index cancers, patients with myeloma constituted <0.1% of the cohort (Table 1) . Patients with myeloma on average were 4 to 14 years older than the general population with each cancer type, and the median latency from the diagnosis of myeloma to that of the SPM ranged from 36 months in patients with lung cancer to 45 months in patients with melanoma. Compared with the general cancer population, there were proportionally more men among the patients with myeloma with bladder cancer or melanoma, but not among those with lung or colorectal cancer. Consistent with the known epidemiology of myeloma, patients with the disease also were significantly more often black. 20 The highest percentage of black patients (27%) among those with myeloma was noted among those individuals with prostate cancer, which shares with myeloma an increased incidence among black Americans. Stage distribution was notable for a higher percentage of patients with early-stage, localized disease among patients with myeloma with breast, lung, and colorectal cancer, but not among patients with melanoma, bladder cancer, or prostate cancer. With regard to available biologic characteristics of the index cancers, the percentage of estrogen receptornegative breast tumors did not differ between patients with myeloma and other patients (18% vs 19%, respectively; P = .98). In the subgroup of patients diagnosed between 2010 and 2015, when the human epidermal growth factor receptor 2 (HER2) status of patients with breast cancer was explicitly recorded, there was no evidence of a different distribution for patients with the triple-negative subtype (14% vs 11%, respectively) or HER2-positive subtype (9% vs 15%, respectively) (P = .11). Among patients with prostate cancer, the median prostate-specific antigen level did not significantly differ either (7.1 ng/mL vs 6.5 ng/mL, respectively; P = .08). In patients with lung cancer, patients with myeloma were found to have a similar percentage of squamous histology compared with other patients (21% vs 20%, respectively), but significantly more adenocarcinomas (51% vs 40%, respectively) and fewer small cell/ neuroendocrine tumors (9% vs 16%, overall) (P < .001).
After matching myeloma cases with controls, we again found that among patients with myeloma, patients with breast cancer (P = .003), prostate cancer (P = .03), and lung cancer (P < .001), but not melanoma (P = .96), colorectal cancer (P = .37), or bladder cancer (P = .65), were more often diagnosed at a localized stage. OS was significantly worse among patients with myeloma for all cancers except for lung cancer, for which it did not differ ( Fig. 1) , and it was worse for all cancers when stratified by stage of disease (Table 2 ). In contrast, CSS did not significantly differ between cases and controls for any cancer except lung cancer, for which it proved significantly better for patients with myeloma. When stratified by stage of disease, CSS still was better among patients with myeloma who were diagnosed with lung cancer, but worse in those diagnosed with breast cancer, and not different in other studied solid tumors.
In the competing risk analysis, which realistically accounted for inherent myeloma-related mortality, the CIF of death from the index cancer was significantly lower among patients with myeloma who were diagnosed with lung cancer, and without any significant difference noted in other studied cancers (Fig. 2) . The risk of death from myeloma at 5 years after the diagnosis of an SPM ranged from 23% in patients with prostate cancer to 35% in patients with melanoma, and was higher than the risk of SPM-related death in all cohorts except those with lung cancer. We observed no significant difference in deaths from noncancer causes in any cohort (subhazard ratios ranging from 0.82 in bladder cancer to 1.41 in breast cancer; all P > .05) (detailed data not shown).
We then compared the use of surgery in patients with early-stage (nonmetastatic) solid tumors among those with myeloma and matched controls, and observed significantly lower odds of surgery for prostate cancer among patients with myeloma (Table 3 ). In patients with other tumors, the use of surgery did not significantly differ between cases and controls. Furthermore, Cancer February 15, 2019 in patients with breast cancer, we found no difference in the percentages of patients undergoing breast conservation surgery (vs mastectomy) between patients with myeloma and controls (OR, 1.07; 95% CI, 0.80-1.42).
In patients with lung cancer, the odds of undergoing lobectomy or pneumonectomy (vs sublobar resection) were significantly lower among patients with myeloma (OR, 0.45; 95% CI, 0.29-0.69). In patients with colorectal cancer, a similar percentage of patients had at least 12 lymph nodes resected for staging during colectomy (68% among patients with myeloma and 72% among controls; P = .32). To assess the stability of our estimates to analytic approach, we repeated all analyses while varying the number of matched controls (1:70) and using matching by exact year of diagnosis, with consistent results (data not shown).
DISCUSSION
In the current population-based study, we compared the characteristics and outcomes of patients with myeloma who developed common solid tumors with matched controls diagnosed with the same cancers. We found consistently worse OS among patients with myeloma, which was related to the myeloma itself. In contrast, the CIF of death from index cancers did not significantly differ between patients with myeloma and controls in the majority of scenarios, and in patients with lung cancer it was significantly lower among patients with myeloma. Cancer February 15, 2019 Outcomes in patients with lung cancer were unique, with a specific distribution of histologies and better CSS, which could not be explained by differences in stage of disease or the disparate use of surgery. The results of the current study provide important guidance both for patients with myeloma who face the challenge of SPMs as well as for oncologists grappling with complex prognosis and treatment options in this population. Prior studies have shown that the incidence of breast, colon, lung, and prostate cancer may be lower among survivors of myeloma compared with the general population. [21] [22] [23] This was hypothetically ascribed to a decrease in cancer screening after diagnosis of a hematologic cancer. 21, 23 Conversely, the nearly 7-fold higher risk of acute leukemia was attributed to the leukemogenic effects of alkylator-based therapy and stem cell transplantation, although the risk of myelodysplasia is notably also increased in patients with monoclonal gammopathy, a premalignant plasma cell dyscrasia. 21, 22, 24 The introduction of proteasome inhibitors and immunomodulatory drugs, which now are used widely for first-line therapy for myeloma in the United States, 25, 26 did not appear to affect the incidence of SPM, although one study suggested that bortezomib treatment may be associated with a lower risk. 10.23 Some clinical trials found an increased rate of SPMs with lenalidomide, yet in a meta-analysis this risk was not observed for patients with common solid tumors. 9, 27, 28 The data from the current study refute the hypothesis of abandonment of cancer screening among patients with myeloma because for the majority of studied cancers, we observed an earlier average stage of disease among patients with myeloma compared with controls. The lower use of prostatectomy among patients with myeloma could be explained by a preference for less invasive, yet equally efficacious, radiotherapy. Alternatively, patients with myeloma with prostate cancer may opt for a more conservative approach with active surveillance rather than curative surgery, thus avoiding common overtreatment of prostate cancer. 29 To our knowledge, the current study is the first to assess survival after diagnosis of an SPM among patients with myeloma. We believe the most important finding is that the CIF of death from a newly diagnosed breast, prostate, colon, or bladder cancer or melanoma did not significantly differ between patients with myeloma and controls, despite the higher overall mortality related to myeloma. The results of the current study are in contrast to those from a study of SPMs in patients with CLL by Solomon et al, who noted worse OS and CSS in patients with breast, prostate, colorectal, lung, or kidney cancer, but did not account for the competing risk of death from CLL. 13 Additional clinical issues specific to CLL (a large percentage of patients observed without treatment, the frequent use of immunosuppressive purine analogues) may contribute to differences between patients with CLL and those with myeloma. We recently described outcomes of SPMs in patients with Waldenstrom macroglobulinemia, demonstrating worse OS but similar or better CSS compared with the general population, with the exception of poor outcomes in patients with colorectal cancer, a finding that is consistent with those of the current study. 11 The results of the current study demonstrate that the risk of death from myeloma quantitatively dominates in the prognosis of patients with myeloma who develop common solid tumors. These findings support curative treatment approaches for incident SPMs diagnosed among patients with myeloma whenever possible, but treatment should be planned after a thorough consideration of the current status, history, and further treatment options for the plasma cell disorder. Ongoing monitoring of myeloma during and after therapy for SPMs is paramount to intervene in the case of disease progression.
The results of the current study provide observational evidence for the International Myeloma Working Group consensus recommendations, which emphasized the risk of myeloma-related death after diagnosis of an SPM. 8 In the current study, we noted that lung cancer, which was associated with the highest disease-specific mortality, demonstrated a unique pattern of outcomes. Although OS after a diagnosis of lung cancer ultimately did not differ between patients with myeloma and controls, and lung cancer-related mortality predominated, the CSS and CIF of cancer-related death were in fact significantly better among patients with myeloma, even after adjustment for stage of disease. This discrepancy highlights the need for studying both OS and cause-specific mortality in the current analysis. We hypothesized that these favorable cause-specific outcomes may reflect 2 phenomena. First, lung cancer was diagnosed at an earlier stage among patients with myeloma, possibly due to regular contact with oncologists and frequent imaging tests. Lead-time bias could persist despite adjustment for stage of disease because the exact tumor size may be highly prognostic in patients with localized lung cancer. Similarly, oligometastatic disease may be associated with a longer survival compared with extensive cancer discovered when debilitating symptoms occur. 30 Second, we observed more adenocarcinomas and fewer neuroendocrine and small cell cancers among patients with myeloma, suggesting a higher incidence of tumors with
Cancer February 15, 2019 epidermal growth factor receptor mutations or other favorable genomic lesions. 31 Hypothetically, differences in histology may relate to varying rates of tobacco use or to alterations in immune surveillance, which is an area of increasing importance in thoracic oncology. 32 It is interesting to note that similar associations in patients with lung cancer were observed among those with Waldenstrom macroglobulinemia, who had similar OS (HR, 1.17; P = .11) but better CSS (HR, 0.73; P = .02) than controls. 11 Further research will be needed to examine the hypothetical biologic, molecular, or immune differences in cancers occurring among patients with myeloma.
The current study has several important limitations. We could not note details concerning therapy for myeloma or solid tumors in the SEER data, but important differences regarding the completeness of cancer surgery or the use of adjuvant modalities (radiotherapy, chemotherapy) might contribute to survival. Our competing risk analysis relied on causes of death recorded on death certificates, which are known to have imperfect accuracy. 33 Because some SEER registries have reported cases only since 2000, an (extremely small) number of controls might have had an unrecorded myeloma diagnosed before then, yet we reassuringly found consistent results excluding all myelomas diagnosed before 2000 (data not shown). Finally, registry-derived data do not provide direct insight into patients' or physicians' preferences when making decisions regarding the treatment of SPMs in patients with myeloma, which is an important perspective warranting further study.
The results of the current study have demonstrated that patients with myeloma who develop breast, prostate, or lung cancer more often are diagnosed at an earlier stage compared with matched controls with the same cancers. OS among patients with myeloma diagnosed with the majority of studied cancers was worse (except for lung cancer), but the CSS and the CIF of cancer-related death were not. Competing risk analysis revealed that excess mortality among patients with myeloma can be ascribed to the myeloma itself rather than other causes. There also was no evidence of the disparate use of cancer surgery in most scenarios. Although the American Society of Clinical Oncology recently recommended broadening the inclusion criteria for clinical trials to include patients with previously treated malignancies, 34 patients with myeloma should be enrolled in an individualized manner because of expected high myeloma-related mortality. The need for further myeloma-directed therapy during or after treatment of an SPM needs to be considered. Conversely, in many cases, patients with myeloma can receive standard therapy for an SPM, which would argue for maintaining age-appropriate cancer screening and providing standard-of-care therapy when a secondary cancer is diagnosed. Further research should evaluate the outcomes of patients with SPMs within the context of myeloma remission status at the time of an SPM diagnosis, the application of specific treatment modalities, and in other hematologic malignancies that now are associated with prolonged survival.
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